DANCAN Share Price Performance
DKK 0.97
-5.23 (-84.27%)
Price DKK 0.97
Share PriceDKK 0.97
DANCAN Community Narratives
There are no narratives available yet.
Recent DANCAN News & Updates
DanCann Pharma A/S Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 25, 2025
- Earnings per share (EPS)
- -1.98
- Gross Margin
- -5.94%
- Net Profit Margin
- -114.39%
- Debt/Equity Ratio
- 0%
DanCann Pharma A/S Competitors
Snowflake Analysis
About DANCAN
- Founded
- 2018
- Employees
- 5
- CEO
- WebsiteView website
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company’s development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros. It is also involved in the import and distribution of Bedrocan CannGros, Bedica CannGros, and Bediol CannGros. The company was incorporated in 2018 and is based in Ansager, Denmark.
Market Insight
This week, we’re going to look at the U.S. regulatory changes, how adoption has been trending, and one of the risks with the ETFs. If you want some exposure to Bitcoin, at the end, we’ll show you some different ways you can position your portfolio accordingly.
Continue reading
Danish Market Performance
- 7 Days: 2.8%
- 3 Months: -10.3%
- 1 Year: -38.3%
- Year to Date: -24.3%
The market has climbed 2.8% in the last 7 days, lead by the Healthcare sector with a gain of 6.0%. On the other hand, with a decline of 8.5%, the Consumer Discretionary sector is lagging behind. In contrast, the market has seen a decline of 38% over the last 12 months. As for the next few years, earnings are expected to grow by 4.9% per annum. Market details ›